Cargando…
Case report: A de novo ERBB3 mutation develops in a gallbladder cancer patient carrying BRCA1 mutation after effective treatment with olaparib
BACKGROUND: Gallbladder cancer (GBC) is highly lethal and resistant to most chemotherapeutic drugs. GBC was reported to carry multiple genetic mutations such as TP53, K-RAS, and ERBB2/3. Here, we unexpectedly identified a patient with GBC harboring germline BRCA1 p.Arg1325Lys heterozygous mutation....
Autores principales: | Yang, Jing-Xiao, Jia, Zi-Yao, Liu, Fa-Tao, Wu, Wen-Guang, Li, Xue-Chuan, Zou, Lu, Li, Huai-Feng, Zhang, Fei, Bao, Run-Fa, Peng, Shu-You, Lau, Wan Yee, Liu, Yun, Li, Mao-Lan, Liu, Ying-Bin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034383/ https://www.ncbi.nlm.nih.gov/pubmed/36969051 http://dx.doi.org/10.3389/fonc.2023.1078388 |
Ejemplares similares
-
Response of BRCA1-mutated gallbladder cancer to olaparib: A case report
por: Xie, Yuan, et al.
Publicado: (2016) -
Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation
por: Li, Xiaofen, et al.
Publicado: (2021) -
Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017) -
Olaparib combined with immunotherapy for treating a patient with liver cancer carrying BRCA2 germline mutation: A case report
por: Zhao, Fengjiao, et al.
Publicado: (2020) -
Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)